Pharming Group

Company Description

Pharming Group is a biopharmaceutical company developing and commercializing treatments for rare diseases, with a focus on conditions where the body lacks a critical protein. The company's unique approach uses transgenic technology—producing human proteins in rabbit milk—to create medicines that can replace what patients' bodies cannot make. The company's flagship product is RUCONEST® (conestat alfa), a recombinant human C1 inhibitor used to treat acute attacks in patients with hereditary angioedema (HAE), a rare genetic condition causing severe swelling. RUCONEST generated record revenues of $252 million in 2024. The company also markets Joenja® (leniolisib), a small molecule for activated PI3K delta syndrome (APDS), which is expanding into new markets. Founded in 1988 in Leiden, Netherlands, Pharming pioneered the technology of pharming—using genetically modified animals to produce pharmaceutical proteins. The company has grown from a research-focused organization into a commercial-stage biopharmaceutical company with operations in the US, France, and the Netherlands. With approximately 400 employees and $297 million in 2024 revenues (up 21%), Pharming is led by CEO Fabrice Chouraqui (who took over in early 2025). The company continues expanding its rare disease portfolio, completing the acquisition of Swedish biotech Abliva AB and launching Joenja in England and Wales in 2025. Pharming's pipeline focuses on primary immunodeficiencies and primary mitochondrial diseases.